The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study

Vos van Steenwijk, Peggy; Poelgeest, Mariette; Ramwadhdoebe, Tamara; Löwik, Margriet; Berends-van der Meer, Dorien; Minne, Caroline; Loof, Nikki; Stynenbosch, Linda; Fathers, Lorraine; Valentijn, A.; Oostendorp, Jaap; Osse, Elisabeth; Fleuren, Gert; Nooij, Linda; Kagie, Marjolein; Hellebrekers, Bart; Melief, Cornelis; Welters, Marij; Burg, Sjoerd; Kenter, Gemma
February 2014
Cancer Immunology, Immunotherapy;Feb2014, Vol. 63 Issue 2, p147
Academic Journal
The capacity of a low-dose HPV16 synthetic long-peptide vaccine (HPV16-SLP) to induce an HPV16-specific T-cell response as well as to establish long-term immunologic memory in patients with low-grade abnormalities of the cervix was determined in a placebo-controlled, double-blinded phase II study. In addition, the effect of a booster vaccination after 1 year was evaluated. Patients received either the HPV16-SLP or a placebo at the start of the study. After 1 year, the vaccinated patients were again randomized to receive the HPV16-SLP or a placebo. Patients were followed for 2 years. HPV16-specific T-cell responses were determined in pre- and post-vaccination blood samples by ELISPOT, proliferation assay and cytokine assays. We show that the HPV16-specific T-cell responses detected after vaccination are clearly due to vaccination and that reactivity was maintained for at least 2 years. Interestingly, a booster vaccination after 1 year especially augmented the HPV16-specific Th2 response. Furthermore, pre-existing immunity to HPV16 was associated with a stronger response to vaccination and with more side effects, reflected by flu-like symptoms. We conclude that two low-dose injections of HPV16-SLP can induce a strong and stable HPV16-specific T-cell response that lasts for at least 1 year. If booster vaccination is required, then polarizing adjuvant should be added to maintain the Th1 focus of the vaccine-induced T-cell response.


Related Articles

  • External Radiation and Brachytherapy Resource Deficit for Cervical Cancer in India: Call to Action for Treatment of All. Chopra, Supriya; Shukla, Richa; Budukh, Atul; Shrivastava, Shyam Kishore // Journal of Global Oncology;6/5/2019, Vol. 5, p1 

    Highlights from the article: Cervical cancer is the fourth most common cancer among women worldwide, with India contributing to 17% of the new cases. We therefore undertook a study to report access to EBRT and BT treatment units in reference to state-level incidence of cervical cancer and...

  • T lymphocytes (CD3) may participate in the recurrence of cervical intraepithelial neoplasia grade III. Maluf, P.; Michelin, M.; Etchebehere, R.; Adad, S.; Murta, E. // Archives of Gynecology & Obstetrics;Dec2008, Vol. 278 Issue 6, p525 

    Data from the literature demonstrate that the local and systemic immune responses seem to play an important role in the progression of cervical intraepithelial neoplasia (CIN). Our aim was to investigate whether recurrences among CIN III patients might be related to the presence of local...

  • A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Vos van Steenwijk, Peggy; Ramwadhdoebe, Tamara; Löwik, Margriet; Minne, Caroline; Berends-van der Meer, Dorien; Fathers, Lorraine; Valentijn, A.; Oostendorp, Jaap; Fleuren, Gert; Hellebrekers, Bart; Welters, Marij; Poelgeest, Mariette; Melief, Cornelis; Kenter, Gemma; Burg, Sjoerd // Cancer Immunology, Immunotherapy;Sep2012, Vol. 61 Issue 9, p1485 

    The aim of this study was to investigate the capacity of an HPV16 E6/E7 synthetic overlapping long-peptide vaccine to stimulate the HPV16-specific T-cell response, to enhance the infiltration of HPV16-specific type 1 T cells into the lesions of patients with HPV16+ high-grade cervical squamous...

  • NVENTA UNVEILS IMMUNOLOGICAL DATA FROM HSPE7 PHASE 1 TRIAL.  // Worldwide Biotech;May2008, Vol. 20 Issue 5, p1 

    The article reports on the release of interim immunological data from the first two cohorts of Nventa Biopharmaceuticals Corporation's ongoing Phase 1 clinical trial of its lead product candidate, HspE7. The product is being tested in patients with cervical intraepithelial neoplasia (CIN). It...

  • Cytokine profile in cervical mucosa of Japanese patients with cervical intraepithelial neoplasia. Iwata, Takashi; Fujii, Takuma; Morii, Kenji; Saito, Miyuki; Sugiyama, Juri; Nishio, Hiroshi; Morisada, Tohru; Tanaka, Kyoko; Yaguchi, Tomonori; Kawakami, Yutaka; Aoki, Daisuke // International Journal of Clinical Oncology;Feb2015, Vol. 20 Issue 1, p126 

    Background: Immune responses in the uterine cervix are considered to play an important role in persistent human papillomavirus (HPV) infection and carcinogenesis, but many aspects of the mechanism are still unclear. The goal of this study was to measure cytokines to analyze immune responses in...

  • Desgarro cervical en paciente con pesario. González-Díaz, I.; Sánchez-Gómez, P.; García-Lorenzo, L.; Esnal-Tres, A.; Escribano-Tórtola, J. J. // Ginecologia y Obstetricia de Mexico;jun2016, Vol. 84 Issue 6, p396 

    BACKGROUND: Preterm birth is a major cause of maternal and fetal morbidity and mortality. It affects 6-10% of pregnant women. The cervical pessary is an effective method to reduce preterm delivery in patients with short cervix. So far the only reported side effects have been increased vaginal...

  • Diffuse large B-cell lymphoma of the uterine cervix: A rare case managed novellv. Baijal, Gunjan; Vadiraja, B. M.; Fernandes, Donald J.; Vidyasagar, M. S. // Journal of Cancer Research & Therapeutics;Apr-Jun2009, Vol. 5 Issue 2, p140 

    Non-Hodgkin's lymphoma (NHL) of the uterine cervix is exceedingly rare. The management of the disease is not standardized. A 44-year-old lady presented with a history of bleeding pervaginum and a foul-smelling discharge of 2 months' duration. A 7 × 7 growth was seen in the cervix. A biopsy...

  • Incidentally Discovered Diffuse Large B-Cell Lymphoma Limited to the Endocervical Mucosa in a Young Female Patient. Pósfai, Éva; Nagy, Károly; Marton, Imelda; Bánfalvi, attila; Kocsis, Lajos; Cserni, Gábor // Gynecologic & Obstetric Investigation;Aug2015, Vol. 80 Issue 2, p134 

    Primary high-grade non-Hodgkin lymphoma of the female genital tract is extremely rare. Vaginal bleeding, abdominal pain or urinary complaints might be its most frequent symptoms. We report a 27-year-old multipara who underwent large loop excision of the transformation zone because of the...

  • Anaerobic (bacterial) vaginosis and premalignant disease... Barrington, J.W.; Linton, D. // Journal of Obstetrics & Gynaecology;Jul97, Vol. 17 Issue 4, p383 

    Presents a study to determine the relationship between cervical intraepithelial neoplasia (CIN) and anaerobic vaginosis (AV). Distribution of AV and CIN in patients and controls; Relationship of smoking and secondary infection and the presence of AV; Treatment for AV.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics